On this page
Marcelo Bigal
Insider
First SEC filing: June 12, 2026 · Latest: June 12, 2026
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | A | 10,891 | · | · | 10,891 Direct | · | Acquired | (price as of 2026-10-05) |
| June 10, 2026 | PCRX | A | 6,405 | · | · | 17,798 Direct | +56.22% | Acquired | (price as of 2026-10-05) |
| Aug. 7, 2025 | PCRX | S | 4,912 | $23.67 | $116,267 | 11,393 Direct | -30.13% | Disposed | 7.5% (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 6,163 | · | · | 16,305 Direct | +60.77% | Acquired | (price as of 2026-10-05) |
| June 11, 2025 | PCRX | A | 11,279 | · | · | 11,279 Direct | · | Acquired | (price as of 2026-10-05) |
| Aug. 16, 2024 | PCRX | P | 1,512 | $13.25 | $20,034 | 10,142 Direct | +17.52% | Acquired | 92.0% (price as of 2026-10-05) |
| Aug. 12, 2024 | PCRX | P | 3,400 | $12.01 | $40,834 | 8,630 Direct | +65.01% | Acquired | 111.8% (price as of 2026-10-05) |
| Aug. 12, 2024 | PCRX | P | 3,400 | $12.01 | $40,834 | 8,630 Direct | +65.01% | Acquired | 111.8% (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 5,230 | · | · | 5,230 Direct | · | Acquired | (price as of 2026-10-05) |
| June 12, 2024 | PCRX | A | 12,179 | · | · | 12,179 Direct | · | Acquired | (price as of 2026-10-05) |
| Oct. 6, 2023 | PCRX | A | 30,967 | · | · | 30,967 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | PCRX | Stock Option (Right to Buy) | Common Stock | $23.42 | June 10, 2036 | 10,891 | Acquired |
| June 11, 2025 | PCRX | Stock Option (Right to Buy) | Common Stock | $24.34 | June 11, 2035 | 11,279 | Acquired |
| June 12, 2024 | PCRX | Stock Option (Right to Buy) | Common Stock | $28.68 | June 12, 2034 | 12,179 | Acquired |
| Oct. 6, 2023 | PCRX | Stock Option (Right to Buy) | Common Stock | $29.80 | Oct. 6, 2033 | 30,967 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).